学会発表
Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer : a subgroup analysis of the JBCRG-C06 Safari study
Takahiro Nakayama, Hidetoshi Kawaguchi, Norikazu Masuda, Shigehira Saji, Yutaka Yamamoto, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Satoshi Morita, Masakazu Toi, Shinji Ohno
2019.12 SABCS Poster San Antonio, Texas
A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with Bevacizumab following fixed cycles of Bevacizumab plus Paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial
Shigehira Saji, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Naruto Taira, Satoshi Morita, Shinji Ohno, Masakazu Toi
2019.12 SABCS Poster San Antonio, Texas
Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2–negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Kokoro Kobayashi, Naoki Niikura, Shigehira Saji, Takayuki Iwamoto, Nobutaka Iwakuma, Yuichiro Kikawa, Norikazu Masuda, Kenichi Watanabe, Takashi Takeshita, Mari Oba, Shinji Ohno
2019.12 SABCS Poster San Antonio, Texas
Meta-analysis of nanoparticle albumin-bound paclitaxel (Nab-PTX) used as a neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01)
Manabu Futamura, Mari Oba, Norikazu Masuda, Hiroko Bando, Morihito Okada, Yutaka Yamamoto, Takanori Kin, Toshiaki Saeki, Takeshi Nagashima, Takashi Kuwayama, Uhi Toh, Akira Hirano, Masafumi Inokuchi, Kazuhiko Yamagami, Yutaka Mizuno, Yasuyuki Kojima, Takahiro Nakayama, Hiroyuki Yasojima, Shinji Ohno
2019.12 SABCS Poster San Antonio, Texas
HER2陰性進行・再発乳癌に対するべバシズマブとパクリタキセル併用療法の前向き観察研究（JBCRG-C05試験：B-SHARE）
唐宇飛、山本豊、山城大泰、近藤直人、中村力也、柏葉匡寛、高橋將人、津川浩一郎、石川孝、中山貴寛、大谷彰一郎、高野利実、藤澤知巳、遠山竜也、川口英俊、増野浩二郎、谷野裕一、森田智視、戸井雅和、大野真司
2019年7月 第27回日本乳癌学会学術総会 口演 東京
HER2陰性再発乳癌患者の1次もしくは2次化学療法としてのエリブリンの臨床的有用性に関する検討(JBCRG-19)
本田弥生、青儀健二郎、渡邊健一、北田正博、三階貴史、大谷彰一郎、有賀智之、森田智視、増田慎三、戸井雅和、大野真司
2019年7月 第27回日本乳癌学会学術総会 ポスター 東京
Trial in progress: A study evaluating Pregnancy, disease Outcome and Safety of Interrupting endocrine Therapy for premenopausal women with endocrine responsIVE breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13, POSITIVE)
Chikako Shimizu, Akemi Kataoka, Takashi Kuwayama, Yasuyuki Kojima, Olivia Pagani, Ann H. Partridge, Hatem A. Azim Jr., Fedro A. Peccatori
第9回日本がん・生殖医療学会学術集会, 2019 Feb, Osaka Japan
Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study
Akihiko Shimomura, Norikazu Masuda, Junpei Kawauchi, Satoko Takizawa, Makiko Ichikawa, Juntaro Matasuzaki, Katsumasa Kuroi, Hisato Hara, Naohito Yamamoto, Kenichi Inoue, Nobuyasu Suganuma, Kenjiro Aogi, Shinji Ohno, Kenji Tamura, Takahiro Ochiya, Masakazu Toi
2018.12 SABCS Poster San Antonio, USA
A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06 / EMERALD)
Norikazu Masuda, Toshinari Yamashita, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno
2018.12 SABCS Poster San Antonio, USA
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8-12 weeks’ exemestane exposure for ER+/HER2-postmenopausal breast cancer patients (JBCRG-11TC)
Hiroyuki Yasojima, Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, and Masakazu Toi
2018.12 SABCS Poster San Antonio, USA